# Pharmacodynamic Properties of CJ-12420 on Evening Dosing

> **NCT03043521** · PHASE1 · COMPLETED · sponsor: **HK inno.N Corporation** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Dexlansoprazole 60 MG
- **DRUG:** CJ-12420 50mg
- **DRUG:** CJ-12420 100mg
- **DRUG:** CJ-12420 200mg

## Key facts

- **NCT ID:** NCT03043521
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-13
- **Primary completion:** 2015-08-12
- **Final completion:** 2015-08-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03043521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03043521, "Pharmacodynamic Properties of CJ-12420 on Evening Dosing". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03043521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*